Equities analysts predict that ENDRA Life Sciences Inc (NASDAQ:NDRA) will post earnings of ($0.21) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ENDRA Life Sciences’ earnings. ENDRA Life Sciences posted earnings per share of ($0.31) during the same quarter last year, which suggests a positive year over year growth rate of 32.3%. The business is scheduled to report its next earnings report on Thursday, August 13th.
On average, analysts expect that ENDRA Life Sciences will report full year earnings of ($0.82) per share for the current year. For the next year, analysts expect that the business will report earnings of ($0.58) per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for ENDRA Life Sciences.
ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.29) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.29).
An institutional investor recently raised its position in ENDRA Life Sciences stock. ICM Asset Management Inc. WA grew its stake in shares of ENDRA Life Sciences Inc (NASDAQ:NDRA) by 32.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 876,639 shares of the company’s stock after purchasing an additional 212,755 shares during the period. ENDRA Life Sciences comprises about 0.6% of ICM Asset Management Inc. WA’s holdings, making the stock its 21st biggest holding. ICM Asset Management Inc. WA owned 6.37% of ENDRA Life Sciences worth $633,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 7.86% of the company’s stock.
Shares of ENDRA Life Sciences stock traded down $0.03 during trading on Friday, hitting $0.93. The stock had a trading volume of 901,000 shares, compared to its average volume of 230,386. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.43 and a quick ratio of 2.32. The firm has a market cap of $13.93 million, a P/E ratio of -0.41 and a beta of 1.80. The business has a fifty day moving average of $0.86 and a two-hundred day moving average of $1.10. ENDRA Life Sciences has a fifty-two week low of $0.60 and a fifty-two week high of $2.25.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
Featured Article: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.